Arrowhead Pharmaceuticals

Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones

Retrieved on: 
Wednesday, November 9, 2022
Molecule, GLOBE, Private Securities Litigation Reform Act, Forward-looking statement, Trim, Royalty Pharma, The New England Journal of Medicine, U.S. Securities and Exchange Commission, Cardiovascular disease, Gene silencing, Nasdaq, Gibson, Dunn & Crutcher, Research, Risk, Moyamoya disease, Gene, EDGAR, Sale, Death, RNA interference, RNA, Annual report, News, Achievement, Safety, Arrowhead Pharmaceuticals, Sirna, Publication, Fenwick & West, Terminology, Patient, NEW, Therapy, Security (finance), Lipoprotein(a), American Heart Association, Armin Maiwald, OCEAN, AbbVie, COVID-19, Pharmaceutical industry, Fine chemical, Amgen, Arrowhead, Ivacaftor

NEW YORK and PASADENA, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasdaq: ARWR) for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.

Key Points: 
  • Olpasiran is a small interfering RNA (siRNA) originally developed by Arrowhead using its proprietary Targeted RNAi Molecule, or TRiM, platform and licensed to Amgen in 2016.
  • Cardiovascular disease remains the most common cause of death worldwide despite certain treatment advances, and new therapeutic targets are greatly needed.
  • Royalty Pharma is acquiring Arrowheads entire royalty interest in olpasiran, which is a royalty up to the low double digits on worldwide net sales.
  • Arrowhead will retain rights to the $400 million in development, regulatory and sales milestone payments potentially due from Amgen.

Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

Retrieved on: 
Wednesday, November 9, 2022
Cardiology, Biotechnology, Pharmaceutical, Finance, Health, Professional Services, Genetics, Clinical Trials, Molecule, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Private Securities Litigation Reform Act, Forward-looking statement, Trim, Royalty Pharma, The New England Journal of Medicine, U.S. Securities and Exchange Commission, Cardiovascular disease, Gene silencing, Gibson, Dunn & Crutcher, Nasdaq, Research, Risk, EDGAR, Moyamoya disease, Gene, Sale, Death, Arrowhead Pharmaceuticals, COVID-19, RNA interference, RNA, Annual report, NASDAQ, News, Achievement, Safety, Sirna, Company, Publication, Fenwick & West, Terminology, Patient, Therapy, Security (finance), Lipoprotein(a), American Heart Association, Armin Maiwald, OCEAN, AbbVie, Fine chemical, Pharmaceutical industry, Amgen, Arrowhead, Ivacaftor

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgens olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgens olpasiran from Arrowhead for $250 million in cash upfront plus up to $160 million in additional payments contingent on the achievement of certain clinical, regulatory, and sales milestones.
  • Olpasiran is a small interfering RNA (siRNA) originally developed by Arrowhead using its proprietary Targeted RNAi Molecule, or TRiM, platform and licensed to Amgen in 2016.
  • Royalty Pharma is acquiring Arrowheads entire royalty interest in olpasiran, which is a royalty up to the low double digits on worldwide net sales.
  • Arrowhead will retain rights to the $400 million in development, regulatory, and sales milestone payments potentially due from Amgen.

Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline

Retrieved on: 
Monday, November 7, 2022
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Molecule, TGS, Investor, NASDAQ, News, ANGPTL3, Private Securities Litigation Reform Act, Arrowhead Pharmaceuticals, U.S. Securities and Exchange Commission, The New England Journal of Medicine, Patient, Company, American Heart Association, Mount Sinai, FCS, Population, Mission statement, Baylor College of Medicine, Diet, Trial of the century, Baylor University, RNA, Gene, Icahn School of Medicine at Mount Sinai, HTG, Drug development, COVID-19, Arrowhead, APOC3, Amgen, Cardiovascular disease, Pain, AHA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., History, Hypertriglyceridemia, Moyamoya disease, Gene silencing, Fasting, Liver disease, Annual report, Therapy, Risk, Lipoprotein lipase, Safety, Security (finance), Lipid, Pharmaceutical industry, RNA interference, Medicine

These data were presented during the Nov. 6 Late-Breaking Science Session and simultaneously published in the New England Journal of Medicine .

Key Points: 
  • These data were presented during the Nov. 6 Late-Breaking Science Session and simultaneously published in the New England Journal of Medicine .
  • The November 9, 2022 analyst and investor event will feature presentations from key opinion leaders, Christie M. Ballantyne, M.D.
  • This interim analysis (data cutoff July 6, 2022) evaluated data when all subjects reached week 12.
  • This interim analysis (data cutoff July 25, 2022) evaluated data when greater than 50% of subjects had reached week 12 and received both doses.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Thursday, October 13, 2022
Genetics, Pharmaceutical, Health, News, Therapy, Employment, NASDAQ, Arrowhead, Arrowhead Pharmaceuticals, RNA interference, RNA, Twitter, Financial compensation, Company, Gene silencing, Gene, Vaccine

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 4, 2022, the Compensation Committee of the Companys Board of Directors approved inducement grants to 39 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 4, 2022, the Compensation Committee of the Companys Board of Directors approved inducement grants to 39 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules.
  • The grants entitle employees, in aggregate, to receive up to 117,500 restricted stock units, including 30,000 restricted stock units granted to Peter Carignan, the Companys new vice president of clinical operations.
  • The grants are outside the Companys stockholder-approved equity incentive plans and vest annually over four years.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3

Retrieved on: 
Tuesday, October 11, 2022
Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, News, U.S. Securities and Exchange Commission, Cardiovascular disease, Risk, Therapy, Investor, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Annual report, NASDAQ, Arrowhead, Arrowhead Pharmaceuticals, Lipid, Hypertriglyceridemia, AHA, RNA, Twitter, Baylor University, APOC3, Security (finance), HTG, Private Securities Litigation Reform Act, RNA interference, Trial of the century, Mission statement, Company, Lipoprotein lipase, Liver disease, Fasting, FCS, American Heart Association, Safety, Diet, TGS, Gene silencing, Icahn School of Medicine at Mount Sinai, Baylor College of Medicine, COVID-19, Gene, ANGPTL3, Mount Sinai, Pharmaceutical industry, Medicine, Cholesterol, Patient, Triglyceride

The company will also host a virtual analyst and investor event on November 9, 2022, at 10:00 am ET to discuss these data and Arrowheads plans for future clinical development.

Key Points: 
  • The company will also host a virtual analyst and investor event on November 9, 2022, at 10:00 am ET to discuss these data and Arrowheads plans for future clinical development.
  • In the Phase 2 ARCHES-2 clinical study ( NCT04832971 ), eligible subjects (n=203) were randomized 3:1 to receive subcutaneous injections of 50, 100, or 200 mg ARO-ANG3 or placebo on day 1 and at week 12.
  • This interim analysis (data cutoff July 6, 2022) evaluated data when all subjects reached week 12.
  • This interim analysis (data cutoff July 25, 2022) evaluated data when greater than 50% of subjects had reached week 12 and received both doses.

Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences

Retrieved on: 
Thursday, September 1, 2022
Professional Services, Health, Genetics, Finance, Pharmaceutical, Banking, Biotechnology, RNA interference, Security (finance), COVID-19, International Congress on Buddhist Women's Role in the Sangha, RNA, Safety, Gene silencing, Gene, NASDAQ, Arrowhead, Morgan Stanley, Arrowhead Pharmaceuticals, ERS, CFA, European Respiratory Society, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Mission statement, Conference, International, Company, Therapy, News, Twitter, Investor, Annual report, Medical device, Pharmaceutical industry

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Key Points: 
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
  • Any statements contained in this release except for historical information may be deemed to be forward-looking statements.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis

Retrieved on: 
Wednesday, August 17, 2022
Pharmaceutical, Health, Clinical Trials, U.S. Securities and Exchange Commission, MMP7, Gene silencing, RNA interference, Gene, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., IPF, Arrowhead Pharmaceuticals, Private Securities Litigation Reform Act, Clinical trial, Ethics committee, Annual report, Security (finance), Patient, Review, COVID-19, Company, Twitter, Therapy, Arrowhead, RNA, Mission statement, Safety, NASDAQ, Committee, News, MBA, Idiopathic pulmonary fibrosis, Degenerative disease, Time, Pharmacokinetics, Pharmaceutical industry

ARO-MMP7 is a further expansion of our robust clinical pipeline, which also includes additional lung disease product candidates, ARO-RAGE and ARO-MUC5AC.

Key Points: 
  • ARO-MMP7 is a further expansion of our robust clinical pipeline, which also includes additional lung disease product candidates, ARO-RAGE and ARO-MUC5AC.
  • Pending clearance, Arrowhead intends to proceed with AROMMP7-1001, a Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7 in up to 56 healthy volunteers and in up to 21 patients with IPF.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results

Retrieved on: 
Thursday, August 4, 2022
Health, Genetics, Other Science, Clinical Trials, Research, Science, Pharmaceutical, The New England Journal of Medicine, Association, Trial of the century, EASL, Annual general meeting, ANGPTL3, Liver disease, European Association for the Study of the Liver, Patient, NEJM, Company, NASDAQ, Arrowhead Pharmaceuticals, Webcast, Conference, Pharmaceutical industry, Liver

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal third quarter ended June 30, 2022.
  • The company is hosting a conference call today, August 4, 2022, at 4:30 p.m.
  • ET to discuss the results.
  • For analysts that wish to participate in the conference call, please dial 888-243-4451 or 412-542-4135 and ask to join the Arrowhead Pharmaceuticals call.

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results

Retrieved on: 
Wednesday, July 20, 2022
Oncology, Health, Infectious Diseases, Genetics, Pharmaceutical, Cardiology, Biotechnology, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Twitter, RNA interference, Arrowhead Pharmaceuticals, Merrell Dow Pharmaceuticals Inc. v. Thompson, Mission statement, Safety, COVID-19, Gene silencing, NASDAQ, Conference, News, Webcast, Gene, Company, Security (finance), Therapy, Annual report, Arrowhead, RNA, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2022, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022.
  • For analysts that wish to participate in the conference call, please dial 888-243-4451 or 412-542-4135 and ask to join the Arrowhead Pharmaceuticals call.
  • We assume no obligation to update or revise forward-looking statements contained in the webcast to reflect new events or circumstances.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Friday, July 8, 2022
Infectious Diseases, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, General Health, Pharmaceutical, Health, Oncology, Financial compensation, Gene, Company, Arrowhead Pharmaceuticals, Employment, Therapy, RNA, RNA interference, Gene silencing, NASDAQ, Twitter, Arrowhead, News, Vaccine

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2022, the Compensation Committee of the Companys Board of Directors approved inducement grants to 34 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on July 1, 2022, the Compensation Committee of the Companys Board of Directors approved inducement grants to 34 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules.
  • The grants entitle employees, in aggregate, to receive up to 138,000 restricted stock units, including 70,000 restricted stock units granted to Tracie Oliver, the Companys new chief commercial officer.
  • The grants are outside the Companys stockholder-approved equity incentive plans and vest annually over four years.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.